Objective: Malignant ovarian germ cell tumors (MOGCT) carry an excellent prognosis, and the treatment aims to achieve results with the least possible treatment-related morbidity. The aim of this study was to assess the outcomes of pediatric patients with MOGCT. 5-year overall survival [OS] 100%), seven relapsed (three patients with Dysg and four patients with Non-Dysg) and were rescued with chemotherapy (plus surgery in three patients). Among the evaluable patients with stages II-IV, 48 (98%) achieved complete remission after chemotherapy ± surgery, one (IT + AFP, stage IV) had progressive disease. In the whole series (median follow-up 80 months), the 5-year OS and EFS were 98.5% (95% CI: 95.6-100%) and 84.5% (95% CI: 76.5-93.5%).
INTRODUCTION
Malignant ovarian germ cell tumors (MOGCT) are rare, accounting for 2-3% of all ovarian malignancies. They usually develop in children and adolescents, or young women 1 with a median age at diagnosis of 16 years (range 6-60 years). Patients are treated at pediatric departments as well as gynecology units. An initial surgery may also sometimes be managed at nonspecialized centers, and inadequate surgical staging is common. 2 Luckily, the survival rates for children with malignant germ cell tumors (GCT) generally have greatly improved.
Based on a previous national experience, 3 a new study on malignant non-CNS GCT launched by the Associazione Italiana Ematologia Oncologia Pediatrica (the "TCGM-AIEOP-2004 study") aimed to extend the age of enrolment from ≤16 to <18 years, to avoid further treatment after surgery for all localized (stage I) MOGCT, and to adopt standard combination chemotherapy (bleomycin-etoposide-cisplatin, BEP) with dose adjustments to limit late effects. The present study examines the outcomes.
METHODS
Patients with MOGCT were registered for the second national were enrolled. Patients with no tumor histology at diagnosis, but with high AFP and/or beta-human chorionic gonadotropin (betaHCG) levels could also be included. AFP and betaHCG were assayed at diagnosis, before each cycle of chemotherapy, or until normalization after completing the treatment(s). Patients were followed up with abdominal ultrasound, chest X-rays, and AFP and betaHCG assay every 2 months in the first year after completing any treatment, every 3 months in the second year, then 6-monthly until the fifth year. After the fifth year, follow-up was at the discretion of the local center. Staging was done with the modified Children's Oncology Group system [4] [5] [6] [7] [8] (Table 1) . Centralized pathology review was encouraged, but not mandatory. (three cycles for stage II, four for stages III and IV, or persistently high markers after surgery). After chemotherapy, resection of radiologically evident residual disease was suggested. Bilateral disease was managed surgically, sparing the less-involved ovary to avoid castration.
Treatment

Response criteria
Patients with normal tumor markers and no imaging abnormalities 
Statistical analysis
Overall survival (OS) was defined as the time elapsing from diagnosis to death from any cause. Time was censored as at the last followup for patients still alive. Event-free survival (EFS) was defined as the time from diagnosis to any event (malignant germ cell recurrence, teratoma, teratoma with malignant transformation, death, whichever occurred first). Time was censored as at the last follow-up for patients still alive and event-free. The OS and EFS curves were estimated using the Kaplan-Meier method, 9 and compared using the log-rank test.
All patients were included in the OS and EFS analyses regardless of whether they complied with the treatment program. EFS was censored at 1 month for two patients (the time elapsing from diagnosis to last follow-up), but their survival status could be retrieved from the records, and they could contribute to the OS curves as censored observations for a longer interval. The median follow-up was estimated with the reverse Kaplan-Meier method, using the OS data. 10 in seven) with elevated AFP levels (median 140 ng/ml, range 50-3,863).
RESULTS
From
Central pathology review was performed for 38 of 77 (49%) cases and all but two diagnoses were confirmed ( Table 2) . (Table 3 ).
The one stage IV case had liver and peritoneal metastases (AFP:
1,440). After surgery, and two BEP cycles, she had PD, so the chemotherapy was changed, achieving PR. Teratoma was identified after delayed surgery. Thirty-four months after diagnosis, the residual infradiaphragmatic disease spread rapidly and she died after an attempted resection. Pathology showed teratoma with malignant transformation (primitive neuroectodermal tumor [pNET]; Table 3 ).
In all IT + AFP patients, the 5-year OS and EFS rates were 92.3%
(95% CI: 78.8-100%) and 82.5% (95% CI: 63.1-100%), respectively.
Non-Dysg: Among 38 patients, 11 were stage I and were monitored closely after surgery, and had no chemotherapy. Two had surgery according to the original surgical guidelines, seven according to the revised version, two underwent OO. Four patients relapsed (one without PWC, one without normalized AFP after surgery, two properly staged) a median 3 months after diagnosis (Table 3) . They all received chemotherapy, and two of four patients also had surgery (one before, one after chemotherapy), with no impact on fertility. All are alive and in
CR.
Six cases were classified as stages II due to tumor ruptures/capsule lacerations in three, peritoneal pelvic implants were removed in one, no PWC in two. One patient was PD after two BEP cycles, with a growing tumor mass despite marker normalization. She underwent surgery, teratoma with malignant transformation was diagnosed, and chemotherapy was administered. The diagnosis was centrally revised to growing teratoma and managed surgically. The teratoma grew again twice. At the time of writing, she was disease-free after a 82-month follow-up (Table 3 ). All patients achieved CR: five after three cycles of BEP, one after chemotherapy and surgery.
The reasons for 17 patients being stage III were as follows: residual mass and/or peritoneal implants in eight, PWC positivity in three, metastatic lymph nodes in three, and because no PWC was performed after tumor rupture in three. Thirteen (76%) achieved CR after chemotherapy. Four (24%) had PR (normalized tumor markers and gross residual disease) and underwent surgery, revealing teratoma in two and fibronecrotic tissue in two.
No stage III patients relapsed with malignant disease. One relapsed twice with growing teratoma, 11 and 39 months after delayed surgery (Table 3) . Among the four patients with stage IV, two were under 11 years of age and had lung metastases, two were older, and one had liver metastases, the other had elevated AFP and betaHCG levels, and unre- 
Overall results
Thirty-nine of 49 (80%) patients achieved CR after chemotherapy alone, and another 9 of 49 (total 98%) after adding delayed surgery.
Histology in the latter revealed fibronecrotic tissue in two (4%), viable malignant cells in two (4%), and teratoma in five (10%). All but one of these patients was alive at the last follow-up (5-year OS 98.5%, 95% CI:
95.6-100%) and the 5-year EFS was 84.5% (95% CI: 76. 
Toxicity
Chemotherapy was well tolerated and there were no toxic deaths, secondary leukemias, or cancers. One female had a severe skin 
DISCUSSION
We describe the second Italian case series of MOGCT. Compared to the first, 3 we found a higher number of cases because of the extended age of enrolment and greater awareness of some gynecologists, though pediatric cases are probably still underreported; a better survival (from a 33-month OS of 88.2% to a 5-year OS of 98.5%; and from 33-month EFS of 80.8% to a 5-year EFS of 84.5%), probably due to a more effective drug regimen; and a lower burden of treatment, since all NonDysg patients had previously received chemotherapy, and stage II Dysg patients had received radiotherapy.
This study confirms the excellent prognosis for Dysg patients, although our P-value was not significant when they were compared to Non-Dysg patients: none had distant metastases at diagnosis, and all stage II and III cases were cured without subsequent events. We recommend a strict follow-up with markers and ultrasound, reserving computed tomography and/or MRI for selected cases. Given the value of tumor markers for monitoring purpose, we prefer to use ultrasound to contain patients' radiological exposure during their follow-up. Even if Dysg patients lack informative AFP (often also betaHCG) levels, they
should be followed up with ultrasound too, although Dysg relapses later and demands a prolonged follow-up. It has already been reported in adults that >90% of relapses in Dysg patients occur within 3 years, and those in Non-Dysg patients appear within 2 years. 12 This was true of our series too, and it is important to bear this in mind to ensure a proper follow-up (Table 3) .
There is no consensus on the management of ovarian IT, and their inclusion in analyses on MOGCT is debated: approaches differ between adults and pediatric professionals, and even between pediatric series. [13] [14] [15] [16] We included IT with elevated AFP because central pathology review was not mandatory and there was a risk of missing some foci of YST within IT 17 : in 2004, we chose to include IT with AFP level cutoff "high for age," which is why we had such a wide range. This is another controversial issue: some national pediatric groups (UK, COG) [16] [17] [18] adopt an AFP cutoff for treating IT, while others do not. We acknowledge that having no cutoff can be misleading and an international agreement is needed.
The surveillance-alone strategy for Non-Dysg histotypes has recently been widely debated. Pediatric specialists and some European groups 7, 13, 17, [19] [20] [21] support this strategy in adults too. Pediatricians worry about the long-term treatment sequelae (neuro-and nephrotoxicity, lung fibrosis, hypertension, and etoposide-related secondary leukemia, 22 ) and try to avoid chemotherapy. Cisplatin is measurable in the serum for years after exposure, and detectable in every bodily organ at autopsy. 23, 24 The cumulative prevalence of serious or lifethreatening chronic medical conditions by 45 years of age among pediatric cancer survivors is reportedly as high as 80%, suggesting premature aging as a consequence of childhood cancer therapies. 25 Some adult specialists are more cautious, especially for YST, and prescribe chemotherapy systematically because recurrences are rare, but potentially lethal. 26, 27 Another argument in favor of chemotherapy is concerned with the potential impact on fertility of further surgery for patients who relapse, 26 and the need for more chemotherapy.
We realize that surveillance alone exposes some females to the risk of recurrence, but in our experience almost all of those who recur are rescued with standard-dose chemotherapy, with/without further surgery, with no impact on fertility. This seems a fair price to pay for the benefit to our patients spared any chemotherapy.
There is another point to consider in patients with residual/recurrent growing masses and a teratoma component in their original tumor: if their tumor markers remain normal, it is not a progression. The so-called chemotherapeutic retroconversion or growing teratoma 28 is not so rare: Zagamé et al. reported an incidence of 12% in their pediatric and adult series, 29 and it was 5% in our series.
Growing teratoma should be managed with surgery, which is both diagnostic and the mainstay of therapy. Subsequent surgery may be needed to remove all localizations and late recurrences, 28 and no randomized trials are available. 19 The role of lymph node dissection is also debated 5 : gynecological oncologists consider it fundamental (especially in Dysg) because dissemination is more often lymphatic than intraperitoneal. 19 But without pathological tumor markers at diagnosis, ovarian masses may be indistinguishable from teratomas (for which lymphadenectomy is unnecessary). In our series, LNS was initially recommended, then omitted if the lymph nodes seemed normal. It is important to discuss these details to prompt pediatric surgeons to examine the nodes during surgery, perform PWC, and carefully assess the retroperitoneal lymph nodes on baseline computed tomography. Given the lack of conclusive scientific data on the most appropriate surgical staging, 19 the patients' age and long life expectancy, and the high cure rates after relapses, as pediatric professionals we advise against excessively aggressive front-line surgery, and favor a minimal invasiveness. More extensive surgery should be reserved for relapsing patients, where necessary.
Noncompliance with surgical guidelines is a known issue for MOGCT and other neoplasms in pediatric and adult patients, 8, [30] [31] [32] [33] [34] and was seen in our sample too. It is of special concern for patients with stage I. The multicenter Italian trial 30 Our patients in stages II-IV were too few to identify any differences, but the proposed prognostic indicators 11, 36 suggest that females with stage IV MOGCT >11 years of age have a worse disease-free survival (<70%). With only five metastatic cases, it is impossible to draw any conclusions, but the only patient with refractory malignant disease was in stage IV and >11 years of age.
The Children's Oncology Group 7 had already compared the use of a compressed BEP regimen with standard BEP, 26, [37] [38] [39] and the Brazilian group omitted bleomycin in intermediate-risk patients. 14 We delivered BEP in 4 days, with a single dose of bleomycin, and reduced the etoposide too. These dose reductions did not seem to influence survival, though randomized trials in adult male series showed worse results after reducing doses of bleomycin and etoposide 40 and alternative combinations did not achieve better results in terms of survival or toxicity. 23, 39 Standard BEP remains the gold standard for adult GCT. 38, 39 Our BEP regimen was changed to minimize the risk of late sequelae and survival rates were excellent after low cumulative doses of etoposide and bleomycin. None of our patients have had secondary leukemia or severe late effects to date, though it is impossible to draw conclusions.
In conclusion, females with MOGCT generally have an excellent outcome, with a low burden of surgery and chemotherapy, and (hopefully) of late sequelae. Robust data and randomized trials are lacking, however, on surgical staging, surveillance for Non-Dysg with stage I, IT management, the "right" AFP cutoff, the type of BEP for young patients.
As pediatric oncologists, we support the role of surveillance after minimal but accurate surgical staging, providing the case is handled by experts at specialized pediatric centers, as already reported by gynecological centers. 31, 41 
